PDCD1 and cancer: Based on this mechanism, immune checkpoint therapy (ICT) combined with PD-1/PD-L1 blockade prevents PD-1 and PD-L1 from interacting, restoring T cells from an exhausted state and reinvigorating the T-cell-mediated immune response against cancer cells [6].